Research ArticleOriginal Article

Somatic copy number alterations are predictive of progression-free survival in patients with lung adenocarcinoma undergoing radiotherapy

Fan Kou, Lei Wu, Yan Guo, Bailu Zhang, Baihui Li, Ziqi Huang, Xiubao Ren and Lili Yang
Cancer Biology & Medicine May 2022, 19 (5) 685-695; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0728

References

  1. 1.↵
    2. Siegel RL,
    3. Miller KD,
    4. Jemal A.
    Cancer statistics, 2018. CA Cancer J Clin. 2018; 68: 7–30.
    OpenUrlCrossRefPubMed
  2. 2.↵
    2. Chan C,
    3. Lang S,
    4. Rowbottom C,
    5. Guckenberger M,
    6. Faivre-Finn C.
    IASLC Advanced Radiation Technology Committee. Intensity-modulated radiotherapy for lung cancer: current status and future developments. J Thorac Oncol. 2014; 9: 1598–608.
    OpenUrlPubMed
  3. 3.↵
    2. De Ruysscher D,
    3. Lueza B,
    4. Le Péchoux C,
    5. Johnson D,
    6. O’Brien M,
    7. Murray N, et al.
    Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis. Ann Oncol. 2016; 27: 1818–28.
    OpenUrlCrossRefPubMed
  4. 4.↵
    2. Wang J,
    3. Zhao Y,
    4. Wang Q,
    5. Zhang L,
    6. Shi J,
    7. Wang Z, et al.
    Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatment. Cancer Biol Med. 2018; 15: 443–51.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    2. Goodman CR,
    3. Seagle BL,
    4. Friedl TWP,
    5. Rack B,
    6. Lato K,
    7. Fink V, et al.
    Association of circulating tumor cell status with benefit of radiotherapy and survival in early-stage breast cancer. JAMA Oncol. 2018; 4: e180163.
  6. 6.↵
    2. Chan CHF,
    3. Wong P.
    Molecular predictors of radiotherapy response in sarcoma. Curr Treat Options Oncol. 2016; 17: 2.
    OpenUrl
  7. 7.↵
    2. Holland AJ,
    3. Cleveland DW.
    Boveri revisited: chromosomal instability, aneuploidy and tumorigenesis. Nat Rev Mol Cell Biol. 2009; 10: 478–87.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    2. Davoli T,
    3. Uno H,
    4. Wooten EC,
    5. Elledge SJ.
    Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science. 2017; 355: eaaf8399.
  9. 9.↵
    2. Hieronymus H,
    3. Murali R,
    4. Tin A,
    5. Yadav K,
    6. Abida W,
    7. Moller H, et al.
    Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death. Elife. 2018; 7: e37294.
  10. 10.↵
    2. Kim H,
    3. Cha H,
    4. Kim J,
    5. Park W,
    6. Choi Y,
    7. Sun J, et al.
    Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing. Eur J Cancer. 2019; 120: 65–74.
    OpenUrlPubMed
  11. 11.↵
    2. Killcoyne S,
    3. Gregson E,
    4. Wedge D,
    5. Woodcock D,
    6. Eldridge M,
    7. de la Rue R, et al.
    Genomic copy number predicts esophageal cancer years before transformation. Nat Med. 2020; 26: 1726–32.
    OpenUrlPubMed
  12. 12.↵
    2. Kou F,
    3. Wu L,
    4. Ren X,
    5. Yang L.
    Chromosome abnormalities: new insights into their clinical significance in cancer. Mol Ther Oncolytics. 2020; 17: 562–70.
    OpenUrl
  13. 13.↵
    2. Thorsson V,
    3. Gibbs DL,
    4. Brown SD,
    5. Wolf D,
    6. Bortone DS,
    7. Ou Yang TH, et al.
    The immune landscape of cancer. Immunity. 2018; 48: 812–30.e14.
    OpenUrlCrossRefPubMed
  14. 14.↵
    2. Hartaigh BÓ,
    3. Gransar H,
    4. Callister T,
    5. Shaw LJ,
    6. Schulman-Marcus J,
    7. Stuijfzand WJ, et al.
    Development and validation of a simple-to-use nomogram for predicting 5-, 10-, and 15-year survival in asymptomatic adults undergoing coronary artery calcium scoring. JACC Cardiovasc Imaging. 2018; 11: 450–8.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    2. An C,
    3. Li X,
    4. Yu X,
    5. Cheng Z,
    6. Han Z,
    7. Liu F, et al.
    Nomogram based on albumin-bilirubin grade to predict outcome of the patients with hepatitis C virus-related hepatocellular carcinoma after microwave ablation. Cancer Biol Med. 2019; 16: 797–810.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    2. Subramanian A,
    3. Tamayo P,
    4. Mootha VK,
    5. Mukherjee S,
    6. Ebert BL,
    7. Gillette MA, et al.
    Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102: 15545–50.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    2. Campbell JD,
    3. Alexandrov A,
    4. Kim J,
    5. Wala J,
    6. Berger AH,
    7. Pedamallu CS, et al.
    Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nat Genet. 2016; 48: 607–16.
    OpenUrlCrossRefPubMed
  18. 18.↵
    2. Swanton C,
    3. Govindan R.
    Clinical implications of genomic discoveries in lung cancer. N Engl J Med. 2016; 374: 1864–73.
    OpenUrlCrossRefPubMed
  19. 19.↵
    2. Shukla AK,
    3. Tripathi D.
    Detecting biomarkers from microarray data using distributed correlation based gene selection. Genes Genomics. 2020; 42: 449–65.
    OpenUrl
  20. 20.
    2. Zaccaria S,
    3. Raphael BJ.
    Accurate quantification of copy-number aberrations and whole-genome duplications in multi-sample tumor sequencing data. Nat Commun. 2020; 11: 4301.
    OpenUrlCrossRefPubMed
  21. 21.
    2. Jiao Q,
    3. Sun H,
    4. Zhang H,
    5. Wang R,
    6. Li S,
    7. Sun D, et al.
    The combination of whole-exome sequencing and copy number variation sequencing enables the diagnosis of rare neurological disorders. Clin Genet. 2019; 96: 140–50.
    OpenUrl
  22. 22.↵
    2. Nam JY,
    3. Kim NK,
    4. Kim SC,
    5. Joung JG,
    6. Xi R,
    7. Lee S, et al.
    Evaluation of somatic copy number estimation tools for whole-exome sequencing data. Brief Bioinform. 2016; 17: 185–92.
    OpenUrlCrossRefPubMed
  23. 23.↵
    2. Pinto AE,
    3. Pires A,
    4. Silva G,
    5. Bicho C,
    6. André S,
    7. Soares J.
    Ploidy and S-phase fraction as predictive markers of response to radiotherapy in cervical cancer. Pathol Res Pract. 2011; 207: 623–7.
    OpenUrlPubMed
  24. 24.
    2. Moureau-Zabotto L,
    3. Bouchet C,
    4. Cesari D,
    5. Uzan S,
    6. Lefranc JP,
    7. Antoine M, et al.
    Combined flow cytometry determination of S-phase fraction and DNA ploidy is an independent prognostic factor in node-negative invasive breast carcinoma: analysis of a series of 271 patients with stage I and II breast cancer. Breast Cancer Res Treat. 2005; 91: 61–71.
    OpenUrlCrossRefPubMed
  25. 25.↵
    2. Subtil-Rodríguez A,
    3. Vázquez-Chávez E,
    4. Ceballos-Chávez M,
    5. Rodríguez-Paredes M,
    6. Martín-Subero JI,
    7. Esteller M, et al.
    The chromatin remodeller CHD8 is required for E2F-dependent transcription activation of S-phase genes. Nucleic Acids Res. 2014; 42: 2185–96.
    OpenUrlCrossRefPubMed
  26. 26.↵
    2. Liu R,
    3. Qu Y,
    4. Chen L,
    5. Pu J,
    6. Ma S,
    7. Zhang X, et al.
    Genomic copy number gains of ErbB family members predict poor clinical outcomes in glioma patients. Oncotarget. 2017; 8: 92275–88.
    OpenUrl
  27. 27.↵
    2. Zafarana G,
    3. Ishkanian AS,
    4. Malloff CA,
    5. Locke JA,
    6. Sykes J,
    7. Thoms J, et al.
    Copy number alterations of c-MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapy. Cancer. 2012; 118: 4053–62.
    OpenUrlCrossRefPubMed
  28. 28.↵
    2. Wang Z,
    3. Zhang L,
    4. He L,
    5. Cui D,
    6. Liu C,
    7. Yin L, et al.
    Low-depth whole genome sequencing reveals copy number variations associated with higher pathologic grading and more aggressive subtypes of lung non-mucinous adenocarcinoma. Chin J Cancer Res. 2020; 32: 334–46.
    OpenUrl
  29. 29.↵
    2. Lei Y,
    3. Sun N,
    4. Zhang G,
    5. Liu C,
    6. Lu Z,
    7. Huang J, et al.
    Combined detection of aneuploid circulating tumor-derived endothelial cells and circulating tumor cells may improve diagnosis of early stage non-small-cell lung cancer. Clin Transl Med. 2020; 10: e128.
  30. 30.↵
    2. Jamal-Hanjani M,
    3. Wilson GA,
    4. McGranahan N,
    5. Birkbak NJ,
    6. Watkins TB,
    7. Veeriah S, et al.
    Tracking the evolution of non-small-cell lung cancer. N Engl J Med. 2017; 376: 2109–21.
    OpenUrlCrossRefPubMed
  31. 31.↵
    2. Hao P,
    3. LeBlanc SJ,
    4. Case BC,
    5. Elston TC,
    6. Hingorani MM,
    7. Erie DA, et al.
    Recurrent mismatch binding by MutS mobile clamps on DNA localizes repair complexes nearby. Proc Natl Acad Sci U S A. 2020; 117: 17775–84.
    OpenUrlAbstract/FREE Full Text
  32. 32.↵
    2. Siegel JJ,
    3. Amon A.
    New insights into the troubles of aneuploidy. Annu Rev Cell Dev Biol. 2012; 28: 189–214.
    OpenUrlCrossRefPubMed
  33. 33.↵
    2. Turajlic S,
    3. Sottoriva A,
    4. Graham T,
    5. Swanton C.
    Resolving genetic heterogeneity in cancer. Nat Rev Genet. 2019; 20: 404–16.
    OpenUrl
  34. 34.↵
    2. He Y,
    3. Liu ZX,
    4. Jiang ZH,
    5. Wang XS.
    Identification of genomic features associated with immunotherapy response in gastrointestinal cancers. World J Gastrointest Oncol. 2019; 11: 270–80.
    OpenUrl
  35. 35.↵
    2. Li B,
    3. Cui Y,
    4. Nambiar DK,
    5. Sunwoo JB,
    6. Li R.
    The immune subtypes and landscape of squamous cell carcinoma. Clin Cancer Res. 2019; 25: 3528–37.
    OpenUrlAbstract/FREE Full Text
  36. 36.↵
    2. Sayles LC,
    3. Breese MR,
    4. Koehne AL,
    5. Leung SG,
    6. Lee AG,
    7. Liu HY, et al.
    Genome-informed targeted therapy for osteosarcoma. Cancer Discov. 2019; 9: 46–63.
    OpenUrlAbstract/FREE Full Text
  37. 37.↵
    2. Wang DS,
    3. Liu ZX,
    4. Lu YX,
    5. Bao H,
    6. Wu X,
    7. Zeng ZL, et al.
    Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer. Gut. 2019; 68: 1152–61.
    OpenUrlAbstract/FREE Full Text
  38. 38.↵
    2. Shao X,
    3. Lv N,
    4. Liao J,
    5. Long J,
    6. Xue R,
    7. Ai N, et al.
    Copy number variation is highly correlated with differential gene expression: a pan-cancer study. BMC Med Genet. 2019; 20: 175.
    OpenUrlCrossRef
  39. 39.↵
    2. Gillette MA,
    3. Satpathy S,
    4. Cao S,
    5. Dhanasekaran SM,
    6. Vasaikar SV,
    7. Krug K, et al.
    Proteogenomic characterization reveals therapeutic vulnerabilities in lung adenocarcinoma. Cell. 2020; 182: 200–25.e35.
    OpenUrlCrossRef
  40. 40.↵
    2. Ben-David U,
    3. Amon A.
    Context is everything: aneuploidy in cancer. Nat Rev Genet. 2020; 21: 44–62.
    OpenUrlPubMed
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords